FDA Approves Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at…
Read More...
Read More...
